BA
TGTX icon

Bridgewater Associates’s TG Therapeutics TGTX Stock Holding History

Bridgewater Associates’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6M Buy
429,904
+118,489
+38% +$4.85M 0.1% 177
2026
Q1 		$10.3M Sell
311,415
-158,440
-34% -$4.72M 0.05% 259
2025
Q4 		$14M Buy
469,855
+127,706
+37% +$4.17M 0.05% 270
2025
Q3 		$12.4M Buy
+342,149
New +$11.3M 0.05% 293

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Bridgewater Associates's TGTX Position: Q2 2026 in Review

Bridgewater Associates increased its TG Therapeutics (TGTX) stake by 38% in Q2 2026, buying an estimated $4.85M and bringing the position to 429,904 shares worth $23.6M. The position accounts for 0.1% of the portfolio, ranked #177.

Bridgewater Associates first reported a position in TGTX in Q3 2025 and has held it in 4 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Bridgewater Associates held 429,904 shares of TG Therapeutics worth $23.6M as of Q2 2026.
  • Bridgewater Associates bought 118,489 TG Therapeutics shares in Q2 2026, an estimated $4.85M.
  • TG Therapeutics made up 0.1% of Bridgewater Associates's portfolio in Q2 2026, its #177 holding.
  • Bridgewater Associates first reported a position in TG Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.